Thursday, June 12, 2025 6:48:14 AM
what most non-revenue biotech investors dont get is that the market has no interest in IP patents as it perhaps had 15 years ago. Heck, the market does not even care about FDA or MHRA approval, there are many examples of biotech with approved drugs that have seen little increase in market value after approval Outlook Therapeutics Inc comes to mind. Another example is Iovance Biotherapeutics with FDA-approved lifileucel (to treat adult patients with unresectable or metastatic melanoma) in February 2024. Market cap $ 750 million now thats 80% down since FDA approval.
Nowadays, the market ONLY responds to huge non-dilutive cash influxes or, better yet, (rumours of) buyouts. If NWBO has not arranged something in that direction upon UK approval to stop the nonstop dilution, I don't see NWBO's market cap increasing significantly after UK approval.
I know I know what the cult will now be saying. Im a basher because after approval, the market will finally see that NWBO is the Amazon of cancer treatment blabla fantasy blabla, which is the same thing they said that will happen upon arrival of JAMA article, blabla, which is utter BS.
Nowadays, the market ONLY responds to huge non-dilutive cash influxes or, better yet, (rumours of) buyouts. If NWBO has not arranged something in that direction upon UK approval to stop the nonstop dilution, I don't see NWBO's market cap increasing significantly after UK approval.
I know I know what the cult will now be saying. Im a basher because after approval, the market will finally see that NWBO is the Amazon of cancer treatment blabla fantasy blabla, which is the same thing they said that will happen upon arrival of JAMA article, blabla, which is utter BS.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
